Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
Verbeterde kwaliteit van leven bij hemofilie B na gentherapie met fidanacogene elaparvovec
dec 2025 | Benigne hematologie